Raehl C L, Moorthy A V, Beirne G J
Nephron. 1986;44(3):191-4. doi: 10.1159/000183984.
The pharmacokinetics of procainamide in patients on continuous ambulatory peritoneal dialysis have been studied. A mean peak plasma concentration of 3.2 +/- 0.6 microgram/ml was achieved about 2 h after a single 500-mg oral procainamide hydrochloride dose. The procainamide elimination half-life ranged from 6.1 to 15.3 h. Apparent oral clearance, 183.7 +/- 63.2 ml/min, was less than half that observed in healthy adults suggesting markedly reduced dosage requirements. Continuous ambulatory dialysis patients exhibit similar procainamide pharmacokinetic parameters as do end stage renal disease patients, most notably a prolonged elimination half-life and reduced oral clearance.
已对持续性非卧床腹膜透析患者中普鲁卡因胺的药代动力学进行了研究。单次口服500毫克盐酸普鲁卡因胺后约2小时,平均血浆峰浓度达到3.2±0.6微克/毫升。普鲁卡因胺的消除半衰期为6.1至15.3小时。表观口服清除率为183.7±63.2毫升/分钟,不到健康成年人的一半,提示所需剂量明显减少。持续性非卧床透析患者的普鲁卡因胺药代动力学参数与终末期肾病患者相似,最显著的是消除半衰期延长和口服清除率降低。